NCT06115642View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

HLX43

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Trial Locations (2)

410008

RECRUITING

Xiangya Hospital Central South University, Changsha

Unknown

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY